RESUMEN
Candida auris, a newly emergent fungal species, has been spreading in health care systems and causing life-threatening infections. Intact innate immunity is essential for protection against many invasive fungal infections, including candidiasis. Here, we highlight recent studies exploring immune interactions with C. auris, including investigations using animal models and ex vivo immune cells. We summarize innate immune studies comparing C. auris and the common fungal pathogen Candida albicans. We also discuss how structures of the C. auris cell wall influence immune recognition, the role of soluble host factors in immune recognition, and areas of future study.
Asunto(s)
Candida auris , Candidiasis , Inmunidad Innata , Humanos , Animales , Candidiasis/inmunología , Candidiasis/microbiología , Candida auris/inmunología , Candida auris/genética , Candida albicans/inmunología , Pared Celular/inmunología , Interacciones Huésped-Patógeno/inmunología , Candida/inmunologíaRESUMEN
Epithelial cells orchestrate immune responses against fungal pathogens. This review highlights advances in integrating epithelial cells in immune responses against inhaled molds and dimorphic fungi, and against Candida species that colonize mucosal surfaces. In the lung, epithelial cells respond to interleukin-1 (IL-1) and interferon signaling to regulate effector cell influx and fungal killing. In the alimentary and vulvovaginal tracts, epithelial cells modulate fungal commensalism, invasive growth, and local immune tone, in part by responding to damage caused by candidalysin, a C. albicans peptide toxin, and through IL-17-dependent release of antimicrobial peptides that contribute to Candida colonization resistance. Understanding fungal-epithelial interactions in mammalian models of disease is critical to predict vulnerabilities and to identify opportunities for immune-based strategies to treat fungal infections.
Asunto(s)
Células Epiteliales , Humanos , Células Epiteliales/microbiología , Células Epiteliales/inmunología , Animales , Candidiasis/inmunología , Candidiasis/microbiología , Hongos/inmunología , Hongos/fisiología , Hongos/patogenicidad , Candida/inmunología , Candida/fisiología , Interacciones Huésped-Patógeno/inmunología , Candida albicans/inmunología , Candida albicans/fisiología , Proteínas Fúngicas/metabolismo , Proteínas Fúngicas/genética , Proteínas Fúngicas/inmunologíaRESUMEN
Epitopes from the Candida cell surface proteins Fba and Met6 are putative vaccine targets for invasive candidiasis. Here, we describe a Candida vaccine approach in which short peptides derived from Fba and Met6 are used in spontaneous nanoliposome antigen particle (SNAP) format. SNAP was enabled by the interaction of cobalt porphyrin phospholipid in liposomes with three histidine residues on the N-terminus of synthetic short peptide immunogens from Fba (F-SNAP), Met6 (M-SNAP), or bivalent Fba and Met6 (FM-SNAP). Liposomes were adjuvanted with synthetic monophosphoryl lipid and QS-21. In mice, immunization with F-SNAP, M-SNAP, or FM-SNAP induced antigen-specific IgG responses and mixed Th1/Th2 immunity. The duplex FM-SNAP vaccine elicited stronger antibody responses against each peptide, even at order-of-magnitude lower peptide dosing than a comparable adjuvanted, conjugate vaccine. Enzyme-linked immunosorbent spot analysis revealed the induction of antigen-specific, cytokine-producing T cells. Compared to F-SNAP or M-SNAP, higher production of TNFα, IL-2, and IFNγ was observed with re-stimulation of splenocytes from bivalent FM-SNAP-immunized mice. When vaccinated BALB/c mice were challenged with Candida auris, analysis of the fungal burden in the kidneys showed that SNAP vaccination protected from disseminated candidiasis. In a lethal fungal exposure model in A/J mice, F-SNAP, M-SNAP, and FM-SNAP vaccination protected mice from candidiasis challenge. Together, these results show that further investigation into the SNAP adjuvant platform is warranted using Fba and Met6 epitopes for a pan-Candida peptide vaccine that provides multifaceted protective immune responses. IMPORTANCE: This study introduces a promising vaccine strategy against invasive candidiasis, a severe fungal infection, by targeting specific peptides on the surface of Candida. Using a novel approach called spontaneous nanoliposome antigen particle (SNAP), we combined peptides from two key Candida proteins, Fba and Met6, into a vaccine. This vaccine induced robust immune responses in mice, including the production of protective antibodies and the activation of immune cells. Importantly, mice vaccinated with SNAP were shielded from disseminated candidiasis in experiments. These findings highlight a potential avenue for developing a broad-spectrum vaccine against Candida infections, which could significantly improve outcomes for patients at risk of these often deadly fungal diseases.
Asunto(s)
Anticuerpos Antifúngicos , Candidiasis , Vacunas Fúngicas , Liposomas , Ratones Endogámicos BALB C , Animales , Ratones , Vacunas Fúngicas/inmunología , Vacunas Fúngicas/administración & dosificación , Liposomas/inmunología , Candidiasis/prevención & control , Candidiasis/inmunología , Femenino , Anticuerpos Antifúngicos/inmunología , Antígenos Fúngicos/inmunología , Vacunas de Subunidad/inmunología , Vacunas de Subunidad/administración & dosificación , Citocinas/inmunología , Vacunación , Proteínas Fúngicas/inmunología , Proteínas Fúngicas/administración & dosificación , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Candida albicans/inmunología , Candida/inmunología , Modelos Animales de EnfermedadRESUMEN
Celiac disease (CD) is an autoimmune enteropathy resulting from an interaction between diet, genome, and immunity. Although many patients respond to a gluten-free diet, in a substantive number of individuals, the intestinal injury persists. Thus, other factors might amplify the ongoing inflammation. Candida albicans is a commensal fungus that is well adapted to the intestinal life. However, specific conditions increase Candida pathogenicity. The hypothesis that Candida may be a trigger in CD has been proposed after the observation of similarity between a fungal wall component and two CD-related gliadin T-cell epitopes. However, despite being implicated in intestinal disorders, Candida may also protect against immune pathologies highlighting a more intriguing role in the gut. Herein, we postulated that a state of chronic inflammation associated with microbial dysbiosis and leaky gut are favorable conditions that promote C. albicans pathogenicity eventually contributing to CD pathology via a mast cells (MC)-IL-9 axis. However, the restoration of immune and microbial homeostasis promotes a beneficial C. albicans-MC cross-talk favoring the attenuation of CD pathology to alleviate CD pathology and symptoms.
Asunto(s)
Candida albicans , Enfermedad Celíaca , Homeostasis , Mastocitos , Enfermedad Celíaca/inmunología , Enfermedad Celíaca/microbiología , Enfermedad Celíaca/metabolismo , Humanos , Candida albicans/patogenicidad , Candida albicans/inmunología , Mastocitos/inmunología , Mastocitos/metabolismo , Microbioma Gastrointestinal/inmunología , Disbiosis/inmunología , Candidiasis/inmunología , Candidiasis/microbiología , Animales , Candida/patogenicidad , Candida/inmunología , Mucosa Intestinal/microbiología , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismoRESUMEN
The delay in making a correct diagnosis of Candida auris causes concern in the healthcare system setting, and immunoproteomics studies are important to identify immunoreactive proteins for new diagnostic strategies. In this study, immunocompetent murine systemic infections caused by non-aggregative and aggregative phenotypes of C. auris and by Candida albicans and Candida haemulonii were carried out, and the obtained sera were used to study their immunoreactivity against C. auris proteins. The results showed higher virulence, in terms of infection signs, weight loss, and histopathological damage, of the non-aggregative isolate. Moreover, C. auris was less virulent than C. albicans but more than C. haemulonii. Regarding the immunoproteomics study, 13 spots recognized by sera from mice infected with both C. auris phenotypes and analyzed by mass spectrometry corresponded to enolase, phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate mutase. These four proteins were also recognized by sera obtained from human patients with disseminated C. auris infection but not by sera obtained from mice infected with C. albicans or Aspergillus fumigatus. Spot identification data are available via ProteomeXchange with the identifier PXD049077. In conclusion, this study showed that the identified proteins could be potential candidates to be studied as new diagnostic or even therapeutic targets for C. auris.
Asunto(s)
Candida , Candidiasis , Inmunoglobulina G , Animales , Ratones , Candida/inmunología , Candida/patogenicidad , Humanos , Candidiasis/inmunología , Candidiasis/microbiología , Candidiasis/sangre , Inmunoglobulina G/sangre , Antígenos Fúngicos/inmunología , Antígenos Fúngicos/sangre , Proteómica/métodos , Candida albicans/inmunología , Candida albicans/patogenicidad , Proteínas Fúngicas/inmunología , Fosfoglicerato Mutasa/inmunología , Fosfoglicerato Quinasa/inmunología , Gliceraldehído-3-Fosfato Deshidrogenasas/inmunología , Gliceraldehído-3-Fosfato Deshidrogenasas/metabolismo , Anticuerpos Antifúngicos/sangre , Anticuerpos Antifúngicos/inmunología , Femenino , VirulenciaRESUMEN
BACKGROUND: No single treatment is ideal for genital warts with high rate of resistance using conventional modalities as topical podophyllin; however, several intralesional immunotherapies are being tested nowadays, with variable results. In this study, we compared the safety and efficacy of treating resistant and recurrent genital warts by 2 intralesional immunotherapies [Candida antigen and measles, mumps, and rubella (MMR) vaccine] and compared them with topical podophyllin. PATIENTS/METHODS: A total of 45 patients with resistant or recurrent genital warts were enrolled in this study. Size and number of warts were detected in each patient, patients were divided into 3 groups. Group A injected with intralesional Candida antigen. Group B with intralesional MMR vaccine. Group C were treated with topical 25% podophyllin. Patients received a session every 2 weeks for 3 treatment sessions. RESULTS: With regard to the reduction in size and number of all warts, the best response was obtained in Candida antigen group where 46.7% showed complete clearance and 40% showed partial response followed by MMR group and the last was the podophyllin group, with no significant difference between them. Complete clearance of mother warts was noticed in 86.7% of Candida group, 53.3% in MMR group, and last 40% in podophyllin group, with a significantly better response in the Candida group (P = .027). CONCLUSION: Both intralesional Candida antigen and MMR vaccine are simple, safe, and effective treatment options with comparable results and better response than topical podophyllin.
Asunto(s)
Antígenos Fúngicos , Condiloma Acuminado , Inyecciones Intralesiones , Vacuna contra el Sarampión-Parotiditis-Rubéola , Podofilino , Humanos , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Masculino , Adulto , Femenino , Antígenos Fúngicos/administración & dosificación , Antígenos Fúngicos/inmunología , Antígenos Fúngicos/uso terapéutico , Condiloma Acuminado/tratamiento farmacológico , Podofilino/administración & dosificación , Podofilino/uso terapéutico , Adulto Joven , Candida/inmunología , Adolescente , Persona de Mediana Edad , Inmunoterapia/métodos , Administración Tópica , Resultado del TratamientoRESUMEN
As candidoses usualmente são tratadas com antifúngicos. No entanto, o efeito desses fármacos é usualmente comprometido pela resistência microbiana e pelos efeitos adversos ocasionados. Nesse sentido, o aumento da prevalência e a complexidade de microrganismos multirresistentes a antimicrobianos têm incitado a busca por terapias complementares e alternativas capazes de atuar efetivamente frente à resistência emergente aos medicamentos. Diante disso, o objetivo desse trabalho foi avaliar comparativamente a ação antimicrobiana e o potencial antibiofilme, in vitro, entre a terapia fotodinâmica antimirobiana (TFDA) com azul de metileno, a fitoterapia, utilizando o extrato hidroetanólico de Spondias mombin L (EHSM), e o probiótico Lactobacillus rhamnosus (PLR) no controle de leveduras do gênero Candida, sendo elas: Candida albicans, Candida tropicalis e Candida parapsilosis. Trata-se de um estudo experimental, in vitro, analítico e quantitativo, em que foram investigadas, em triplicata, a atividade inibidora do crescimento microbiano e a atividade antibiofilme das seguintes terapias alternativas: TFDA, EHSM e PLR, utilizando como controle positivo a Nistatina 100.000UI/mL. Quanto à análise estatística, além da interpretação descritiva, foi aplicado o teste Two-Way ANOVA e o Teste de Tukey. Dessa forma, observou-se que todas as terapias testadas exibiram atividades antifúngica e antibiofilme. Todavia, quando comparadas tais atividades entre elas e ainda com a Nistatina, verificou-se que: a TFDA apresentou a maior atividade inibitória de crescimento microbiano (p<0,05), semelhante a Nistatina, seguida pelo EHSM, exibindo o PLR a menor atividade antifúngica e a TFDA juntamente com o EHSM representaram as terapias com maior atividade antibiofilme (p<0,0001), atuando ambas de forma semelhante a Nistatina. Nesse sentido, foi possível concluir que todas as terapias estudadas possuem atividades antifúngica e antibiofilme frente às cepas do gênero Candida testadas, com destaque para a atividade inibidora de crescimento microbiano da TFDA e a atividade antibiofilme da TFDA e do EHSM, sendo tais atividades semelhantes às atividades da Nistatina (AU).
Candidoses are usually treated with antifungals. However, the effect of these drugs is usually compromised by microbial resistance and adverse effects. In this sense, the increase in the prevalence and complexity of multidrug-resistant microorganisms to antimicrobials have incited the search for complementary and alternative therapies capable of acting effectively against the emerging resistance to medicines. Therefore, the objective of this study was to comparatively evaluate the antimicrobial action and antibiofilm potential, in vitro, between antimyrobial photodynamic therapy (PDT) with methylene blue, phytotherapy, using hydroethanolic extract of Spondias mombin L (EHSM)and the probiotic Lactobacillus rhamnosus (PLR) in the control of yeasts of the genus Candida: Candida albicans, Candida tropicalis and Candida parapsilosis. This is an experimental, in vitro, analytical and quantitative study in which the inhibitory activity of microbial growth and antibiofilm activity of the following alternative therapies were investigated in triplicate: TFDA, EHSM and PLR, using 100.000UI/mL as positive control. Regarding the statistical analysis, in addition to the descriptive interpretation, the Two-Way ANOVA test and the Tukey test were applied. Thus, it was observed that all therapies tested exhibited antifungal and antibiofilm activities. However, when comparing these activities between them and still with Nystatin, it was found that: TFDA showed the highest inhibitory activity of microbial growth (p <0.05), similar to Nystatin, followed by the EHSM, exhibiting the PLR the lowest antifungal activity and the TFDA together with the EHSM represented the therapies with higher antibiofilm activity (p <0.0001), acting both similarly to Nystatin. In this sense, it was possible to conclude that all the therapies studied have antifungal and antibiofilm activities against the strains of the genus Candida tested, especially the inhibitory activity of microbial growth of TFDA and the antibiofilm activity of TFDA and EHSM, similar to the activities of Nistatina (AU).
Asunto(s)
Fotoquimioterapia/instrumentación , Candida/inmunología , Biopelículas , Lacticaseibacillus rhamnosus , Antibacterianos , Análisis de Varianza , Azul de MetilenoRESUMEN
We recently discovered a novel form of trained innate immunity (TII) induced by low-virulence Candida species (i.e., Candida dubliniensis) that protects against lethal fungal/bacterial infection. Mice vaccinated by intraperitoneal (i.p.) inoculation are protected against lethal sepsis following Candida albicans/Staphylococcus aureus (Ca/Sa) intra-abdominal infection (IAI) or Ca bloodstream infection (BSI). The protection against IAI is mediated by long-lived Gr-1+ leukocytes as putative myeloid-derived suppressor cells (MDSCs) and not by prototypical trained macrophages. This study aimed to determine if a similar TII mechanism (Gr-1+ cell-mediated suppression of sepsis) is protective against BSI and whether this TII can also be induced following intravenous (i.v.) vaccination. For this, mice were vaccinated with low-virulence Candida strains (i.p. or i.v.), followed by lethal challenge (Ca/Sa i.p. or Ca i.v.) 14 days later, and observed for sepsis (hypothermia, sepsis scoring, and serum cytokines), organ fungal burden, and mortality. Similar parameters were monitored following depletion of macrophages or Gr-1+ leukocytes during lethal challenge. The results showed that mice vaccinated i.p. or i.v. were protected against lethal Ca/Sa IAI or Ca BSI. In all cases, protection was mediated by Ly6G+ Gr-1+ putative granulocytic MDSCs (G-MDSCs), with no role for macrophages, and correlated with reduced sepsis parameters. Protection also correlated with reduced fungal burden in spleen and brain but not liver or kidney. These results suggest that Ly6G+ G-MDSC-mediated TII is induced by either the i.p. and i.v. route of inoculation and protects against IAI or BSI forms of systemic candidiasis, with survival correlating with amelioration of sepsis and reduced organ-specific fungal burden. IMPORTANCE Trained innate immunity (TII) is induced following immunization with live attenuated microbes and represents a clinically important strategy to enhance innate defenses. TII was initially demonstrated following intravenous inoculation with low-virulence Candida albicans, with protection against a subsequent lethal C. albicans intravenous bloodstream infection (BSI) mediated by monocytes with enhanced cytokine responses. We expanded this by describing a novel form of TII induced by intraperitoneal inoculation with low-virulence Candida that protects against lethal sepsis induced by polymicrobial intra-abdominal infection (IAI) via Gr-1+ leukocytes as putative myeloid-derived suppressor cells (MDSCs). In this study, we addressed these two scenarios and confirmed an exclusive role for Ly6G+ Gr-1+ leukocytes in mediating TII against either IAI or BSI via either route of inoculation, with protection associated with suppression of sepsis. These studies highlight the previously unrecognized importance of Ly6G+ MDSCs as central mediators of a novel form of TII termed trained tolerogenic immunity.
Asunto(s)
Antígenos Ly/inmunología , Candida/inmunología , Candidiasis/inmunología , Candidiasis/prevención & control , Inmunidad Innata , Leucocitos/inmunología , Receptores de Quimiocina/inmunología , Vacunación/métodos , Animales , Candida/patogenicidad , Modelos Animales de Enfermedad , Femenino , Ratones , Infecciones Estafilocócicas/inmunología , Infecciones Estafilocócicas/prevención & control , VirulenciaRESUMEN
Candida auris is a multidrug-resistant fungal pathogen that can cause disseminated bloodstream infections with up to 60% mortality in susceptible populations. Of the three major classes of antifungal drugs, most C. auris isolates show high resistance to azoles and polyenes, with some clinical isolates showing resistance to all three drug classes. We reported in this study a novel approach to treating C. auris disseminated infections through passive transfer of monoclonal antibodies (mAbs) targeting cell surface antigens with high homology in medically important Candida species. Using an established A/J mouse model of disseminated infection that mimics human candidiasis, we showed that C3.1, a mAb that targets ß-1,2-mannotriose (ß-Man3), significantly extended survival and reduced fungal burdens in target organs, compared to control mice. We also demonstrated that two peptide-specific mAbs, 6H1 and 9F2, which target hyphal wall protein 1 (Hwp1) and phosphoglycerate kinase 1 (Pgk1), respectively, also provided significantly enhanced survival and reduction of fungal burdens. Finally, we showed that passive transfer of a 6H1+9F2 cocktail induced significantly enhanced protection, compared to treatment with either mAb individually. Our data demonstrate the utility of ß-Man3- and peptide-specific mAbs as an effective alternative to antifungals against medically important Candida species including multidrug-resistant C. auris.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Antifúngicos/farmacología , Candida/inmunología , Candidiasis Invasiva/prevención & control , Proteínas de la Membrana/inmunología , Animales , Anticuerpos Monoclonales/inmunología , Candida/efectos de los fármacos , Candidiasis Invasiva/inmunología , Candidiasis Invasiva/microbiología , Femenino , Masculino , Ratones , Ratones Endogámicos C57BLRESUMEN
Our data reveal that selection of enzymes for generating single cell suspensions from murine tissues influences detection of surface expression of antifungal CLRs. Using a method that most preserves receptor expression, we show that non-myeloid expression of antifungal CLRs is limited to MelLec on endothelial cells in murine mucosal tissues.
Asunto(s)
Células Endoteliales/metabolismo , Células Epiteliales/metabolismo , Hongos/inmunología , Lectinas Tipo C/metabolismo , Membrana Mucosa/inmunología , Animales , Aspergillus/inmunología , Candida/inmunología , Cryptococcus/inmunología , Ratones , Membrana Mucosa/metabolismo , Membrana Mucosa/microbiologíaRESUMEN
BACKGROUNDThe fungal cell wall constituent 1,3-ß-d-glucan (BDG) is a pathogen-associated molecular pattern that can stimulate innate immunity. We hypothesized that BDG from colonizing fungi in critically ill patients may translocate into the systemic circulation and be associated with host inflammation and outcomes.METHODSWe enrolled 453 mechanically ventilated patients with acute respiratory failure (ARF) without invasive fungal infection and measured BDG, innate immunity, and epithelial permeability biomarkers in serially collected plasma samples.RESULTSCompared with healthy controls, patients with ARF had significantly higher BDG levels (median [IQR], 26 pg/mL [15-49 pg/mL], P < 0.001), whereas patients with ARF with high BDG levels (≥40 pg/mL, 31%) had higher odds for assignment to the prognostically adverse hyperinflammatory subphenotype (OR [CI], 2.88 [1.83-4.54], P < 0.001). Baseline BDG levels were predictive of fewer ventilator-free days and worse 30-day survival (adjusted P < 0.05). Integrative analyses of fungal colonization and epithelial barrier disruption suggested that BDG may translocate from either the lung or gut compartment. We validated the associations between plasma BDG and host inflammatory responses in 97 hospitalized patients with COVID-19.CONCLUSIONBDG measurements offered prognostic information in critically ill patients without fungal infections. Further research in the mechanisms of translocation and innate immunity recognition and stimulation may offer new therapeutic opportunities in critical illness.FUNDINGUniversity of Pittsburgh Clinical and Translational Science Institute, COVID-19 Pilot Award and NIH grants (K23 HL139987, U01 HL098962, P01 HL114453, R01 HL097376, K24 HL123342, U01 HL137159, R01 LM012087, K08HK144820, F32 HL142172, K23 GM122069).
Asunto(s)
COVID-19 , Candida , Inmunidad Innata/inmunología , Respiración Artificial , beta-Glucanos/sangre , Biomarcadores/sangre , COVID-19/inmunología , COVID-19/terapia , Candida/inmunología , Candida/aislamiento & purificación , Permeabilidad Capilar/inmunología , Enfermedad Crítica/terapia , Femenino , Microbioma Gastrointestinal/inmunología , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Respiración Artificial/efectos adversos , Respiración Artificial/métodos , Insuficiencia Respiratoria/etiología , Insuficiencia Respiratoria/terapia , Sistema Respiratorio/inmunología , Sistema Respiratorio/microbiología , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Análisis de SupervivenciaRESUMEN
Vaginal candidiasis is an extremely common disease predominantly caused by four phylogenetically diverse species: Candida albicans; Candida glabrata; Candida parapsilosis; and Candida tropicalis. Using a time course infection model of vaginal epithelial cells and dual RNA sequencing, we show that these species exhibit distinct pathogenicity patterns, which are defined by highly species-specific transcriptional profiles during infection of vaginal epithelial cells. In contrast, host cells exhibit a homogeneous response to all species at the early stages of infection, which is characterized by sublethal mitochondrial signalling inducing a protective type I interferon response. At the later stages, the transcriptional response of the host diverges in a species-dependent manner. This divergence is primarily driven by the extent of epithelial damage elicited by species-specific mechanisms, such as secretion of the toxin candidalysin by C. albicans. Our results uncover a dynamic, biphasic response of vaginal epithelial cells to Candida species, which is characterized by protective mitochondria-associated type I interferon signalling and a species-specific damage-driven response.
Asunto(s)
Candida/genética , Candidiasis Vulvovaginal/microbiología , Células Epiteliales/inmunología , Interferón Tipo I/inmunología , Mitocondrias/inmunología , Candida/inmunología , Candida/aislamiento & purificación , Candida/patogenicidad , Candidiasis Vulvovaginal/genética , Candidiasis Vulvovaginal/inmunología , Células Epiteliales/microbiología , Femenino , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Humanos , Interferón Tipo I/genética , Mitocondrias/genética , Especificidad de la Especie , Vagina/inmunología , Vagina/microbiología , VirulenciaRESUMEN
BACKGROUND: Intralesional immunotherapy has been effectively used in the treatment of warts; however, comparative studies between different antigens are limited. OBJECTIVE: To evaluate the efficacy and safety of intralesional measles, mumps, and rubella (MMR) vaccine compared with intralesional Candida antigen for the treatment of multiple common and plantar warts. METHODS: Sixty-eight adult patients with multiple common and plantar warts were randomly assigned into two groups, each containing 34 patients. The first group received intralesional MMR vaccine, while the second group received intralesional Candida antigen. Each treatment was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. RESULTS: The overall therapeutic response was higher in the Candida antigen group (73.5%) compared with the MMR group (67.7%); however, the difference was not statistically significant. Complete clearance of common warts was higher in the Candida antigen group, while that of plantar warts was higher in the MMR group. Adverse effects were transient and well tolerated in both groups. No recurrence was detected during the 6-month follow-up period. CONCLUSION: Intralesional MMR and intralesional Candida antigen showed comparable efficacy and safety in the treatment of common and plantar warts.
Asunto(s)
Antígenos Fúngicos/administración & dosificación , Candida/inmunología , Inmunoterapia/métodos , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Verrugas/tratamiento farmacológico , Adolescente , Adulto , Anciano , Femenino , Humanos , Inyecciones Intralesiones , Masculino , Persona de Mediana EdadRESUMEN
Chronic mucocutaneous candidiasis (CMC) is characterized by a chronic or recurrent non-invasive infection, mainly due to Candida albicans, in skin, nails, and mucous membranes, associated in some cases with autoimmune manifestations. The key immune defect is a disruption of the action of cytokine IL-17, whose most common genetic etiology is STAT1 gene gain-of-function (GOF) mutations. The initial appropriate treatment for fungal infections is with azoles. However, the frequent occurrence of drug resistance is the main limitation. Therefore, identification of the underlying inborn error if immunity in CMC may allow to widen therapeutic options aimed at restoring immunological function. Type I and II Janus kinase-inhibitors have been shown to control CMC in cases associated with STAT1 GOF. In this review, we delve into the pathogenesis of CMC and the underlying immune mechanisms. We describe the reported genetic defects in which CMC is the main manifestation. Diagnostic and therapeutic approaches for these patients are also offered.
Asunto(s)
Candidiasis Mucocutánea Crónica/inmunología , Enfermedades de Inmunodeficiencia Primaria/inmunología , Azoles/uso terapéutico , Candida/inmunología , Candida/aislamiento & purificación , Candidiasis Mucocutánea Crónica/diagnóstico , Candidiasis Mucocutánea Crónica/genética , Candidiasis Mucocutánea Crónica/terapia , Humanos , Interleucina-17/genética , Interleucina-17/inmunología , Inhibidores de las Cinasas Janus/uso terapéutico , Mutación , Enfermedades de Inmunodeficiencia Primaria/diagnóstico , Enfermedades de Inmunodeficiencia Primaria/genética , Enfermedades de Inmunodeficiencia Primaria/terapia , Factor de Transcripción STAT1/genética , Factor de Transcripción STAT1/inmunología , Células Th17/inmunología , Células Th17/patologíaRESUMEN
Candida auris is an emerging multi-drug-resistant human fungal pathogen. C. auris skin colonization results in environmental shedding, which underlies hospital transmissions, and predisposes patients to subsequent infections. We developed a murine skin topical exposure model for C. auris to dissect risk factors for colonization and to test interventions that might protect patients. We demonstrate that C. auris establishes long-term residence within the skin tissue compartment, which would elude clinical surveillance. The four clades of C. auris, with geographically distinct origins, differ in their abilities to colonize murine skin, mirroring epidemiologic findings. The IL-17 receptor signaling and specific arms of immunity protect mice from long-term C. auris skin colonization. We further determine that commonly used chlorhexidine antiseptic serves as a protective and decolonizing agent against C. auris. This translational model facilitates an integrated approach to develop strategies to combat the unfolding global outbreaks of C. auris and other skin-associated microbial pathogens.
Asunto(s)
Candida/inmunología , Candidiasis/transmisión , Piel/inmunología , Piel/microbiología , Tropismo Viral , Animales , Antiinfecciosos Locales/farmacología , Antifúngicos/farmacología , Candida/efectos de los fármacos , Candidiasis/prevención & control , Clorhexidina/farmacología , Modelos Animales de Enfermedad , Interleucina-17/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores de Interleucina-17/inmunología , Factores de Riesgo , Piel/patología , Células Th17/inmunologíaRESUMEN
BACKGROUND: Intralesional immunotherapy using different types of antigens is considered an effective and safe treatment option for different types of warts. However, there are few studies that illustrate the use of these antigens in the treatment of periungual warts as a distinct type of warts. OBJECTIVE: To evaluate the efficacy and safety of three antigens: measles, mumps, rubella (MMR) vaccine, Candida antigen, and purified protein derivative (PPD) in the treatment of periungual warts. METHODS: The study included 150 patients who were randomly assigned to 3 groups with 50 patients in each. Each agent was injected intralesionally at a dose of 0.1 mL into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. RESULTS: Complete clearance of warts was observed in 70%, 80%, and 74% in PPD, Candida antigen, and MMR vaccine groups, respectively. There was no statistically significant difference regarding the therapeutic response between the 3 studied groups. Adverse effects were transient and insignificant in the 3 groups. No recurrence of the lesions was reported in any of the studied groups. CONCLUSIONS: Intralesional antigen immunotherapy seems to be an effective therapeutic option for the treatment of periungual warts.
Asunto(s)
Antígenos Fúngicos/uso terapéutico , Inmunoterapia/métodos , Vacuna contra el Sarampión-Parotiditis-Rubéola/uso terapéutico , Enfermedades de la Uña/terapia , Enfermedades de la Uña/virología , Verrugas/terapia , Adolescente , Antígenos Fúngicos/administración & dosificación , Candida/inmunología , Niño , Preescolar , Femenino , Humanos , Inyecciones Intralesiones , Masculino , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Adulto JovenRESUMEN
BACKGROUND: Warts is the commonest cutaneous manifestation of human papillomavirus (HPV) infection. Intralesional Candida antigen immunotherapy is used for wart treatment. AIM: To identify the role of mannose binding lectin (MBL) in susceptibility to HPV infection and to explore the relationship between MBL and response to intralesional Candida antigen immunotherapy of wart. PATIENTS AND METHODS: A case-control study was enrolled with 96 participants; 48 wart cases and 48 healthy controls. MBL serum level assay baseline and after six settings of intralesional candida antigen injection was done by ELISA technique. MBL2 gene exon 1 codon 54 polymorphism was detected by using restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). RESULTS: A statistically significant difference in MBL serum level between wart cases and controls was found. An association between MBL2 exon1 codon 54 polymorphism and susceptibility to HPV infection and development of warts was proved. Carriage of genotype AB was more frequent wart cases (95.8%) than in controls (20.8%). No statistical significance association could be found between the therapeutic response to Candida antigen immunotherapy in wart cases and MBL as regards its serum level and genotypes. CONCLUSIONS: MBL play an important role in host defense against HPV infection.
Asunto(s)
Inmunoterapia/métodos , Lectina de Unión a Manosa/sangre , Verrugas/terapia , Adolescente , Adulto , Antígenos Fúngicos/administración & dosificación , Candida/inmunología , Estudios de Casos y Controles , Niño , Ensayo de Inmunoadsorción Enzimática , Femenino , Genotipo , Humanos , Inyecciones Intralesiones , Masculino , Persona de Mediana Edad , Polimorfismo Genético , Polimorfismo de Longitud del Fragmento de Restricción , Adulto JovenRESUMEN
In rodent models, tail vein injections are important methods for intravenous administration of experimental agents. Tail vein injections typically involve warming of the animal to promote vasodilation, which aids in both the identification of the blood vessels and positioning of the needle into the vessel lumen while securely restraining the animal. Although tail vein injections are common procedures in many protocols and are not considered highly technical if performed correctly, accurate and consistent injections are crucial to obtain reproducible results and minimize variability. Conventional methods for inducing vasodilation prior to tail vein injections generally depend on the use of a heat source such as a heat lamp, electrical/rechargeable heat pads, or pre-heated water at 37 °C. Despite being readily accessible in a standard laboratory setting, these tools evidently suffer from poor/limited thermo-regulatory capacity. Similarly, although various forms of restraining devices are commercially available, they must be used carefully to avoid trauma to the animals. These limitations of the current methods create unnecessary variables in experiments or result in varying outcomes between experiments and/or laboratories. In this article, we demonstrate an improved protocol using an innovative device that combines an independent, thermally regulated, warming device with an adjustable restraining unit into one system for efficient streamlined tail vein injection. The example we use is an intravenous model of fungal bloodstream infection that results in sepsis. The warming apparatus consists of a heat-reflective acrylic box installed with an adjustable automatic thermostat to maintain the internal temperature at a pre-set threshold. Likewise, the width and height of the cone restraining apparatus can be adjusted to safely accommodate various rodent sizes. With the advanced and versatile features of the device, the technique shown here could become a useful tool across a range of research areas involving rodent models that employ tail vein injections.
Asunto(s)
Calor , Inyecciones/instrumentación , Sepsis/microbiología , Cola (estructura animal)/irrigación sanguínea , Venas/patología , Animales , Candida/inmunología , Modelos Animales de Enfermedad , Vacunas Fúngicas/inmunología , Inyecciones Intravenosas , Ratones Endogámicos C57BL , Agujas , Ratas , Sepsis/complicaciones , VacunaciónRESUMEN
Children with chronic mucocutaneous candidiasis (CMC) experience recurrent infections with Candida spp. Moreover, immune dysregulation in the early life of these patients induces various autoimmune diseases and affects normal growth and development. The adaptive and innate immune system components play a significant role in anti-fungal response. This response is mediated through IL-17 production by T helper cells. Inborn errors in IL-17-mediated pathways or Candida spp. sensing molecules are known to cause CMC. In this review, we describe underlying immune mechanisms of monogenic primary immune deficiency disorders known to cause CMC. We will explore insights into current management of these patients and novel available therapies.
Asunto(s)
Candidiasis Mucocutánea Crónica/etiología , Susceptibilidad a Enfermedades , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Autoanticuerpos/inmunología , Autoinmunidad , Biomarcadores , Candida/inmunología , Candidiasis Mucocutánea Crónica/tratamiento farmacológico , Manejo de la Enfermedad , Susceptibilidad a Enfermedades/inmunología , Predisposición Genética a la Enfermedad , Interacciones Huésped-Patógeno , Humanos , Terapia Molecular DirigidaRESUMEN
Oropharyngeal candidiasis is the most common opportunistic fungal infectious disease. Culture methods and microscopy are used to detect the presence of Candida species in clinical specimens. We have previously developed an immunochromatographic test (ICT) to enable the simple and rapid diagnosis of candidiasis. In this study, we evaluated the performance of the ICT for the detection of Candida species from pharyngeal swabs and compared the results with those of the culture method. The isolated Candida species were identified using polymerase chain reaction-restriction fragment length polymorphism, and viable cell counts were determined using selective chromogenic agar. The detection rate of C. albicans was 63.3% and 0% among ≤102 and ≥ 106 colony-forming units (CFU)/mL of viable Candida cells from pharyngeal swabs, respectively. The detection rate of nonC. albicans Candida species, especially C. glabrata, increased commensurately from 16.7% at ≤102 CFU/mL to 75.0% at ≥106 CFU/mL. Among the 300 pharyngeal swabs analyzed, 59 cultures detected Candida species at a count of >103 CFU/mL (53 were ICT-positive). Of the remaining 241 culture-negative specimens, 219 were ICT-negative. The sensitivity, specificity, and accuracy of the ICT were 89.8%, 90.9%, and 90.7%, respectively. Taken together, the ICT evaluated can be made readily available for clinical use in detecting Candida.